# US 2021/0259959 A1 · Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0259959 A1
- Document ID: US20210259959A1
- Status: Published application
- Kind: A1
- Application number: 17/315,804
- Filed: 2021-05-10
- Published: 2021-08-26
- Earliest claimed: 2017-06-09
- Assignees: Crititech, Inc.
- Applicants: Crititech, Inc.
- Inventors: Gere S. diZerega; Michael Baltezor; Charles J. Decedue; Sam Campbell; Matthew McClorey; Marc Iacobucci; Holly Maulhardt
- Web page: https://patentgrep.com/patent/US20210259959A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61B 8/0841: {for locating instruments}
- A61B 8/12: in body cavities or body tracts, e.g. by using catheters
- A61K 9/10: Dispersions; Emulsions
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 35/00: Antineoplastic agents
- A61K 9/1688: {resulting in pure drug agglomerate optionally containing up to 5% of excipient}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.

## Claims

### Claim 1

A method for treating an epithelial cyst, the method comprising injecting a composition comprising an effective amount of antineoplastic particles directly into the cyst, thereby treating the epithelial cyst, wherein the particles have a mean particle size (number) of from 0.1 microns to 5 microns.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition further comprises a liquid carrier, and wherein the composition comprises a suspension of the antineoplastic particles dispersed in the carrier.

### Claim 3 (depends on 2)

The method of claim 2, wherein the carrier is an aqueous carrier.

### Claim 4 (depends on 3)

The method of claim 3, wherein the aqueous carrier comprises 0.9% saline solution.

### Claim 5 (depends on 3, 4)

The method of any one of claims 3 or 4, wherein the aqueous carrier comprises a surfactant.

### Claim 6 (depends on 5)

The method of claim 5, wherein the surfactant is a polysorbate.

### Claim 7 (depends on 6)

The method of claim 6, wherein the polysorbate is polysorbate 80, and wherein the polysorbate 80 is present in the aqueous carrier at a concentration of between about 0.01% v/v and about 1% v/v.

### Claim 8 (depends on 3, 4, 5, 6, 7)

The method of any one of claims 3 to 7, wherein the composition further comprises a diluent, wherein the carrier and the diluent form a mixture, and wherein the composition is a suspension of the antineoplastic particles dispersed in the carrier/diluent mixture.

### Claim 9 (depends on 8)

The method of claim 8, wherein the diluent is a 0.9% saline solution.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claim 1 to 9, wherein the antineoplastic particles are taxane particles.

### Claim 11 (depends on 10)

The method of claim 10, wherein the taxane particles comprise at least 95% of the taxane, wherein the taxane particles have a mean particle size (number) of from 0.1 microns to 1.5 microns, and wherein the composition and taxane particles exclude albumin.

### Claim 12 (depends on 10, 11)

The method of any one of claims 10 to 11, wherein the concentration of taxane particles in the composition is between about 6 mg/mL and about 15 mg/mL.

### Claim 13 (depends on 10, 11, 12)

The method of any one of claims 10 to 12, wherein the taxane particles are paclitaxel particles.

### Claim 14 (depends on 13)

The method of claim 13, wherein the paclitaxel particles have a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g; or from about 18 m2/g to about 50 m2/g.

### Claim 15 (depends on 13, 14)

The method of any one of claims 13 to 14, wherein the paclitaxel particles have a bulk density (not-tapped) of 0.05 g/cm3 to 0.15 g/cm3.

### Claim 16 (depends on 10, 11, 12)

The method of any one of claims 10 to 12, wherein the taxane particles are docetaxel particles.

### Claim 17 (depends on 16)

The method of claim 16, wherein the docetaxel particles have a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 35 m2/g, 40 m2/g, or 42 m2/g; or from about 18 m2/g and about 60 m2/g.

### Claim 18 (depends on 16, 17)

The method of any one of claims 16 to 17. wherein the docetaxel particles have a bulk density (not-tapped) of 0.05 g/cm3 to 0.15 g/cm3.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1 to 18, wherein the cyst fluid is withdrawn from the cyst prior to injecting the composition.

### Claim 20 (depends on 19)

The method of claim 19, wherein the volume of the composition injected into the cyst is equal to the volume of cyst fluid removed from the cyst.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1 to 20, wherein the epithelial cyst is a pancreatic cyst.

### Claim 22 (depends on 21)

The method of claim 21, wherein the pancreatic cyst is a mucinous pancreatic cyst.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1 to 22, wherein the injection of the composition is conducted by endoscopic ultrasound-guided fine needle injection (EUS-FNI).

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1 to 25, wherein the epithelial cyst is reduced in volume/size, has reduced growth rate, is eliminated, or is ablated after injection of the composition, and/or wherein the pain associated with the cyst is reduced.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1 to 24, wherein the epithelial cyst is benign.

### Claim 26

A kit comprising:
(a) a first vial comprising taxane particles;
(b) a second vial comprising a pharmaceutically acceptable aqueous carrier and a surfactant; and
(c) instructions for reconstituting the taxane particles into a suspension useful for intracystic injection by: combining the contents of the first vial and the second vial to form the suspension and optionally diluting the suspension with a diluent.

### Claim 27 (depends on 26)

The kit of claim 26, wherein the aqueous carrier is 0.9% saline solution, wherein the surfactant is a polysorbate, and wherein the polysorbate is at a concentration of between about 0.01% v/v and about 1% v/v.

### Claim 28 (depends on 26, 27)

The kit of any one of claims 26 to 27, wherein the diluent is 0.9% saline solution.

### Claim 29 (depends on 26, 27, 28)

The kit of any one of claims 26 to 28, wherein the taxane particles comprise at least 95% of the taxane, wherein the taxane particles have a mean particle size (number) of from 0.1 microns to 1.5 microns, and wherein the taxane particles exclude albumin.

### Claim 30 (depends on 26, 27, 28, 29)

The kit of any one of claims 26 to 29, wherein the taxane particles are solid, uncoated (neat) individual particles: wherein the taxane particles are not bound to any substance; wherein no substances are absorbed or adsorbed onto the surface of the taxane particles; wherein the taxane particles are not encapsulated, contained, enclosed or embedded within any substance; wherein the taxane particles are not coated with any substance; wherein the taxane particles are not microemulsions, nanoemulsions, microspheres, or liposomes; wherein the taxane particles are not bound to, encapsulated in, or coated with a monomer, a polymer (or biocompatible polymer), a protein, a surfactant, or albumin; and/or wherein a monomer, a polymer (or biocompatible polymer), a protein, a surfactant, or albumin is not absorbed or adsorbed onto the surface of the taxane particles.

### Claim 31 (depends on 26, 27, 28, 29, 30)

The kit of any one of claims 26 to 30, wherein the taxane particles are paclitaxel particles.

### Claim 32 (depends on 31)

The kit of claim 31, wherein the paclitaxel particles have a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g; or from about 18 m2/g to about 50 m2/g.

### Claim 33 (depends on 31, 32)

The kit of any one of claims 31 to 32, wherein the paclitaxel particles have a bulk density (not-tapped) of 0.05 g/cm3 to 0.15 g/cm3.

### Claim 34 (depends on 26, 27, 28, 29, 30)

The kit of any one of claims 26 to 30, wherein the taxane particles are docetaxel particles.

### Claim 35 (depends on 34)

The kit of claim 34, wherein the docetaxel particles have a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 35 m2/g, 40 m2g, or 42 m2/g; or from about 18 m2/g and about 60 m2/g.

### Claim 36 (depends on 34, 35)

The kit of any one of claims 34 to 35, wherein the docetaxel particles have a bulk density (not-tapped) of 0.05 g/cm3 to 0.15 g/cm3.

### Claim 37

A method of administering a composition comprising antineoplastic particles to an epithelial cyst of a subject, the method comprising injecting the composition into the cyst using endoscopic ultrasound guided-fine needle injection, wherein the antineoplastic particles have a mean particle size (number) of from 0.1 microns to 5 microns, and wherein the antineoplastic particles are crystalline particles.

### Claim 38 (depends on 37)

The method of claim 37, wherein the antineoplastic particles have a mean particle size (number) of from 0.3 microns to 5 microns.

### Claim 39 (depends on 37, 38)

The method of any one of claims 37 or 38, wherein the antineoplastic particles are taxane particles.
